US 12,435,351 B2
Single-molecule platform for drug discovery: methods and apparatuses for drug discovery, including discovery of anticancer and antiviral agents
Anita Goel, Cambridge, MA (US)
Assigned to NANOBIOSYM, INC., Cambridge, MA (US)
Filed by Nanobiosym, Inc., Cambridge, MA (US)
Filed on Oct. 20, 2023, as Appl. No. 18/491,404.
Application 18/491,404 is a continuation of application No. 16/850,895, filed on Apr. 16, 2020, granted, now 11,807,892.
Application 16/850,895 is a continuation of application No. 15/860,205, filed on Jan. 2, 2018, abandoned.
Application 15/860,205 is a continuation of application No. 11/790,071, filed on Apr. 23, 2007, granted, now 9,862,984, issued on Jan. 9, 2018.
Claims priority of provisional application 60/793,720, filed on Apr. 21, 2006.
Prior Publication US 2024/0309420 A1, Sep. 19, 2024
Int. Cl. C12Q 1/00 (2006.01); C12Q 1/48 (2006.01)
CPC C12Q 1/00 (2013.01) [C12Q 1/48 (2013.01); G01N 2333/16 (2013.01); G01N 2333/91245 (2013.01); G01N 2500/02 (2013.01)] 25 Claims
OG exemplary drawing
 
1. A system for accelerating discovery and validation of drug candidates, the system comprising:
a measurement apparatus configured to extend and secure a nucleic acid molecule and measure a length of the extended nucleic acid molecule;
a sample chamber;
a fluidics delivery apparatus; and
a computing device connected to the measurement apparatus and configured so that during operation of the system, with a nucleic acid molecule secured and extended by the measurement apparatus in the sample chamber and a target enzyme in the sample chamber, the computing device is configured to:
obtain a control activity profile comprising a measurement of a time-dependent length of the extended nucleic acid molecule during an interaction between the nucleic acid molecule and a single molecule of the target enzyme;
introduce a drug candidate into the sample chamber via the fluidics delivery apparatus;
measure a candidate activity profile for the drug candidate comprising a measurement of a time-dependent length of the extended nucleic acid molecule during an interaction between the nucleic acid molecule and a single molecule of the target enzyme in the presence of the drug candidate; and
compare the candidate activity profile to the control activity profile to determine whether the drug candidate modifies the target enzyme's interaction with the nucleic acid molecule.
 
15. A method for accelerating discovery and validation of drug candidates, the method comprising:
securing and extending a nucleic acid molecule in a sample chamber and introducing a target enzyme into the sample chamber;
obtaining a control activity profile comprising a measurement of a time-dependent length of the extended nucleic acid molecule during an interaction between the nucleic acid molecule and a single molecule of the target enzyme;
introducing a drug candidate into the sample chamber;
obtaining a candidate activity profile by measuring a time-dependent length of the extended nucleic acid molecule during an interaction between the nucleic acid molecule and a single molecule of the target enzyme in the presence of the drug candidate; and
comparing the candidate activity profile to the control activity profile, and determining whether the drug candidate modifies the target enzyme's interaction with the nucleic acid molecule.